MedTrace Logo

Sacubitril-valsartan in Patients With Heart Failure.

NCT07341893 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-04-21

No results posted yet for this study

Summary

The aim of this study is to evaluate the safety and efficacy of Sacubitril -Valsartan in patients with heart failure.

Conditions

Interventions

DRUG

Sacubitril-valsartan

patients (n=30) will be given Sacubitril-valsartan 50 mg twice daily.

DRUG

standard treatment of heart failure

Control group (n=30) on standard treatment of heart failure.

Sponsors & Collaborators

  • Damanhour University

    lead OTHER

Principal Investigators

  • Nouran A. Abu Shaara, Bachlore · Damanhour University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-01
Primary Completion
2026-03-01
Completion
2026-03-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07341893 on ClinicalTrials.gov